Selected research
Industry Research
ADC Drug CDMO Service Industry Research Report 2026
Market perspective
The global ADC Drug CDMO Service market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the ADC Drug CDMO Service market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the ADC Drug CDMO Service market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the ADC Drug CDMO Service market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of ADC Drug CDMO Service include Lonza Group, Merck KGaA, WuXi XDC, Abbvie, Piramal Pharma Solutions, Catalent, Sterling Pharma Solutions, Axplora and Aji Bio-Pharma, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global ADC Drug CDMO Service market in terms of revenue (US$ million) and, where applicable, service volume (k units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to ADC Drug CDMO Service.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
ADC Drug CDMO Service Market by Company
Lonza Group
Merck KGaA
WuXi XDC
Abbvie
Piramal Pharma Solutions
Catalent
Sterling Pharma Solutions
Axplora
Aji Bio-Pharma
BSP Pharmaceuticals
Cerbios-Pharma
Goodwin Biotechnology
TOT Biopharm
Huadong Medicine
Innovent Biologics
Shanghai Henlius Biotech
ADC Drug CDMO Service Segment by Type
Cleavable Linkers
Non-cleavable Linkers
ADC Drug CDMO Service Segment by Application
Small and Medium-sized Pharmaceutical Companies
Large Pharmaceutical Companies
ADC Drug CDMO Service Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global ADC Drug CDMO Service market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of ADC Drug CDMO Service and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of ADC Drug CDMO Service.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of ADC Drug CDMO Service companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Cleavable Linkers
- Non-cleavable Linkers
Applications
- Small and Medium-sized Pharmaceutical Companies
- Large Pharmaceutical Companies
Companies covered
- Lonza Group
- Merck KGaA
- WuXi XDC
- Abbvie
- Piramal Pharma Solutions
- Catalent
- Sterling Pharma Solutions
- Axplora
- Aji Bio-Pharma
- BSP Pharmaceuticals
- Cerbios-Pharma
- Goodwin Biotechnology
- TOT Biopharm
- Huadong Medicine
- Innovent Biologics
- Shanghai Henlius Biotech
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 ADC Drug CDMO Service by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Cleavable Linkers
- 2.2.3 Non-cleavable Linkers
- 2.3 ADC Drug CDMO Service by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Small and Medium-sized Pharmaceutical Companies
- 2.3.3 Large Pharmaceutical Companies
- 2.4 Assumptions and Limitations
3 ADC Drug CDMO Service Breakdown Data by Type
- 3.1 Global ADC Drug CDMO Service Historic Market Size by Type (2021-2026)
- 3.2 Global ADC Drug CDMO Service Forecasted Market Size by Type (2027-2032)
4 ADC Drug CDMO Service Breakdown Data by Application
- 4.1 Global ADC Drug CDMO Service Historic Market Size by Application (2021-2026)
- 4.2 Global ADC Drug CDMO Service Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global ADC Drug CDMO Service Market Perspective (2021-2032)
- 5.2 Global ADC Drug CDMO Service Growth Trends by Region
- 5.2.1 Global ADC Drug CDMO Service Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 ADC Drug CDMO Service Historic Market Size by Region (2021-2026)
- 5.2.3 ADC Drug CDMO Service Forecasted Market Size by Region (2027-2032)
- 5.3 ADC Drug CDMO Service Market Dynamics
- 5.3.1 ADC Drug CDMO Service Industry Trends
- 5.3.2 ADC Drug CDMO Service Market Drivers
- 5.3.3 ADC Drug CDMO Service Market Challenges
- 5.3.4 ADC Drug CDMO Service Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top ADC Drug CDMO Service Players by Revenue
- 6.1.1 Global Top ADC Drug CDMO Service Players by Revenue (2021-2026)
- 6.1.2 Global ADC Drug CDMO Service Revenue Market Share by Players (2021-2026)
- 6.2 Global ADC Drug CDMO Service Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of ADC Drug CDMO Service Head Office and Area Served
- 6.4 Global ADC Drug CDMO Service Players, Product Type & Application
- 6.5 Global ADC Drug CDMO Service Manufacturers Established Date
- 6.6 Global ADC Drug CDMO Service Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America ADC Drug CDMO Service Market Size (2021-2032)
- 7.2 North America ADC Drug CDMO Service Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America ADC Drug CDMO Service Market Size by Country (2021-2026)
- 7.4 North America ADC Drug CDMO Service Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe ADC Drug CDMO Service Market Size (2021-2032)
- 8.2 Europe ADC Drug CDMO Service Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe ADC Drug CDMO Service Market Size by Country (2021-2026)
- 8.4 Europe ADC Drug CDMO Service Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific ADC Drug CDMO Service Market Size (2021-2032)
- 9.2 Asia-Pacific ADC Drug CDMO Service Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific ADC Drug CDMO Service Market Size by Country (2021-2026)
- 9.4 Asia-Pacific ADC Drug CDMO Service Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America ADC Drug CDMO Service Market Size (2021-2032)
- 10.2 South America ADC Drug CDMO Service Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America ADC Drug CDMO Service Market Size by Country (2021-2026)
- 10.4 South America ADC Drug CDMO Service Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa ADC Drug CDMO Service Market Size (2021-2032)
- 11.2 Middle East & Africa ADC Drug CDMO Service Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa ADC Drug CDMO Service Market Size by Country (2021-2026)
- 11.4 Middle East & Africa ADC Drug CDMO Service Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Lonza Group
- 12.1.1 Lonza Group Company Information
- 12.1.2 Lonza Group Business Overview
- 12.1.3 Lonza Group Revenue in ADC Drug CDMO Service Business (2021-2026)
- 12.1.4 Lonza Group ADC Drug CDMO Service Product Portfolio
- 12.1.5 Lonza Group Recent Developments
- 12.2 Merck KGaA
- 12.2.1 Merck KGaA Company Information
- 12.2.2 Merck KGaA Business Overview
- 12.2.3 Merck KGaA Revenue in ADC Drug CDMO Service Business (2021-2026)
- 12.2.4 Merck KGaA ADC Drug CDMO Service Product Portfolio
- 12.2.5 Merck KGaA Recent Developments
- 12.3 WuXi XDC
- 12.3.1 WuXi XDC Company Information
- 12.3.2 WuXi XDC Business Overview
- 12.3.3 WuXi XDC Revenue in ADC Drug CDMO Service Business (2021-2026)
- 12.3.4 WuXi XDC ADC Drug CDMO Service Product Portfolio
- 12.3.5 WuXi XDC Recent Developments
- 12.4 Abbvie
- 12.4.1 Abbvie Company Information
- 12.4.2 Abbvie Business Overview
- 12.4.3 Abbvie Revenue in ADC Drug CDMO Service Business (2021-2026)
- 12.4.4 Abbvie ADC Drug CDMO Service Product Portfolio
- 12.4.5 Abbvie Recent Developments
- 12.5 Piramal Pharma Solutions
- 12.5.1 Piramal Pharma Solutions Company Information
- 12.5.2 Piramal Pharma Solutions Business Overview
- 12.5.3 Piramal Pharma Solutions Revenue in ADC Drug CDMO Service Business (2021-2026)
- 12.5.4 Piramal Pharma Solutions ADC Drug CDMO Service Product Portfolio
- 12.5.5 Piramal Pharma Solutions Recent Developments
- 12.6 Catalent
- 12.6.1 Catalent Company Information
- 12.6.2 Catalent Business Overview
- 12.6.3 Catalent Revenue in ADC Drug CDMO Service Business (2021-2026)
- 12.6.4 Catalent ADC Drug CDMO Service Product Portfolio
- 12.6.5 Catalent Recent Developments
- 12.7 Sterling Pharma Solutions
- 12.7.1 Sterling Pharma Solutions Company Information
- 12.7.2 Sterling Pharma Solutions Business Overview
- 12.7.3 Sterling Pharma Solutions Revenue in ADC Drug CDMO Service Business (2021-2026)
- 12.7.4 Sterling Pharma Solutions ADC Drug CDMO Service Product Portfolio
- 12.7.5 Sterling Pharma Solutions Recent Developments
- 12.8 Axplora
- 12.8.1 Axplora Company Information
- 12.8.2 Axplora Business Overview
- 12.8.3 Axplora Revenue in ADC Drug CDMO Service Business (2021-2026)
- 12.8.4 Axplora ADC Drug CDMO Service Product Portfolio
- 12.8.5 Axplora Recent Developments
- 12.9 Aji Bio-Pharma
- 12.9.1 Aji Bio-Pharma Company Information
- 12.9.2 Aji Bio-Pharma Business Overview
- 12.9.3 Aji Bio-Pharma Revenue in ADC Drug CDMO Service Business (2021-2026)
- 12.9.4 Aji Bio-Pharma ADC Drug CDMO Service Product Portfolio
- 12.9.5 Aji Bio-Pharma Recent Developments
- 12.10 BSP Pharmaceuticals
- 12.10.1 BSP Pharmaceuticals Company Information
- 12.10.2 BSP Pharmaceuticals Business Overview
- 12.10.3 BSP Pharmaceuticals Revenue in ADC Drug CDMO Service Business (2021-2026)
- 12.10.4 BSP Pharmaceuticals ADC Drug CDMO Service Product Portfolio
- 12.10.5 BSP Pharmaceuticals Recent Developments
- 12.11 Cerbios-Pharma
- 12.11.1 Cerbios-Pharma Company Information
- 12.11.2 Cerbios-Pharma Business Overview
- 12.11.3 Cerbios-Pharma Revenue in ADC Drug CDMO Service Business (2021-2026)
- 12.11.4 Cerbios-Pharma ADC Drug CDMO Service Product Portfolio
- 12.11.5 Cerbios-Pharma Recent Developments
- 12.12 Goodwin Biotechnology
- 12.12.1 Goodwin Biotechnology Company Information
- 12.12.2 Goodwin Biotechnology Business Overview
- 12.12.3 Goodwin Biotechnology Revenue in ADC Drug CDMO Service Business (2021-2026)
- 12.12.4 Goodwin Biotechnology ADC Drug CDMO Service Product Portfolio
- 12.12.5 Goodwin Biotechnology Recent Developments
- 12.13 TOT Biopharm
- 12.13.1 TOT Biopharm Company Information
- 12.13.2 TOT Biopharm Business Overview
- 12.13.3 TOT Biopharm Revenue in ADC Drug CDMO Service Business (2021-2026)
- 12.13.4 TOT Biopharm ADC Drug CDMO Service Product Portfolio
- 12.13.5 TOT Biopharm Recent Developments
- 12.14 Huadong Medicine
- 12.14.1 Huadong Medicine Company Information
- 12.14.2 Huadong Medicine Business Overview
- 12.14.3 Huadong Medicine Revenue in ADC Drug CDMO Service Business (2021-2026)
- 12.14.4 Huadong Medicine ADC Drug CDMO Service Product Portfolio
- 12.14.5 Huadong Medicine Recent Developments
- 12.15 Innovent Biologics
- 12.15.1 Innovent Biologics Company Information
- 12.15.2 Innovent Biologics Business Overview
- 12.15.3 Innovent Biologics Revenue in ADC Drug CDMO Service Business (2021-2026)
- 12.15.4 Innovent Biologics ADC Drug CDMO Service Product Portfolio
- 12.15.5 Innovent Biologics Recent Developments
- 12.16 Shanghai Henlius Biotech
- 12.16.1 Shanghai Henlius Biotech Company Information
- 12.16.2 Shanghai Henlius Biotech Business Overview
- 12.16.3 Shanghai Henlius Biotech Revenue in ADC Drug CDMO Service Business (2021-2026)
- 12.16.4 Shanghai Henlius Biotech ADC Drug CDMO Service Product Portfolio
- 12.16.5 Shanghai Henlius Biotech Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst